Combining new treatments with temozolomide for colorectal cancer
Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
['FUNDING_CAREER'] · YALE UNIVERSITY · NIH-10886551
This study is looking at how pairing a chemotherapy drug called temozolomide with other treatments can help people with colorectal cancer feel better, especially by targeting the ways cancer cells repair themselves.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10886551 on ClinicalTrials.gov |
What this research studies
This research investigates how combining temozolomide, a chemotherapy drug, with other agents can improve treatment outcomes for patients with colorectal cancer. It focuses on understanding the role of DNA repair mechanisms in cancer and how inhibiting these pathways can enhance the effectiveness of temozolomide. The study includes clinical trials where patients with specific genetic markers will receive these novel drug combinations to assess their safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colorectal cancer who have specific genetic markers indicating silenced MGMT.
Not a fit: Patients with colorectal cancer who do not have the targeted genetic markers or those with advanced disease not amenable to these treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for colorectal cancer patients, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results with similar approaches, particularly in targeting DNA repair mechanisms in various cancers.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CECCHINI, MICHAEL — YALE UNIVERSITY
- Study coordinator: CECCHINI, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.